Overview
POMT2-related limb-girdle muscular dystrophy R14 (LGMDR14), formerly known as LGMD2N, is a rare autosomal recessive muscular dystrophy caused by biallelic pathogenic variants in the POMT2 gene. POMT2 encodes protein O-mannosyltransferase 2, an enzyme essential for the proper glycosylation of alpha-dystroglycan, a key protein that links the muscle cell cytoskeleton to the extracellular matrix. Defective glycosylation of alpha-dystroglycan leads to a group of conditions collectively known as dystroglycanopathies. LGMDR14 represents the milder end of the POMT2-related disease spectrum, with the more severe end including Walker-Warburg syndrome and muscle-eye-brain disease. Patients with LGMDR14 typically present in childhood or adolescence with progressive proximal muscle weakness predominantly affecting the limb-girdle muscles — the muscles around the hips and shoulders. This leads to difficulty climbing stairs, rising from the floor, running, and lifting the arms overhead. Elevated serum creatine kinase (CK) levels are a hallmark laboratory finding. Cognitive impairment of variable severity, including intellectual disability, may be present in some patients, reflecting the role of alpha-dystroglycan in brain development. Muscle biopsy typically shows dystrophic changes with reduced immunostaining for glycosylated alpha-dystroglycan. There is currently no cure or disease-specific treatment for LGMDR14. Management is supportive and multidisciplinary, including physical therapy to maintain mobility and prevent contractures, orthopedic interventions as needed, respiratory monitoring, cardiac surveillance, and neurodevelopmental support when cognitive involvement is present. Genetic counseling is recommended for affected families. Research into therapies targeting the dystroglycanopathy pathway, including gene therapy and pharmacological approaches to enhance glycosylation, is ongoing but remains in early stages.
Also known as:
Clinical phenotype terms— hover any for plain English:
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Variable
Can begin at different ages, from infancy through adulthood
Treatments
No FDA-approved treatments are currently listed for POMT2-related limb-girdle muscular dystrophy R14.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for POMT2-related limb-girdle muscular dystrophy R14 at this time.
New trials open frequently. Follow this disease to get notified.
Rare Disease Specialist
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to POMT2-related limb-girdle muscular dystrophy R14.
Community
No community posts yet. Be the first to share your experience with POMT2-related limb-girdle muscular dystrophy R14.
Start the conversation →Latest news about POMT2-related limb-girdle muscular dystrophy R14
No recent news articles for POMT2-related limb-girdle muscular dystrophy R14.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about POMT2-related limb-girdle muscular dystrophy R14
What is POMT2-related limb-girdle muscular dystrophy R14?
POMT2-related limb-girdle muscular dystrophy R14 (LGMDR14), formerly known as LGMD2N, is a rare autosomal recessive muscular dystrophy caused by biallelic pathogenic variants in the POMT2 gene. POMT2 encodes protein O-mannosyltransferase 2, an enzyme essential for the proper glycosylation of alpha-dystroglycan, a key protein that links the muscle cell cytoskeleton to the extracellular matrix. Defective glycosylation of alpha-dystroglycan leads to a group of conditions collectively known as dystroglycanopathies. LGMDR14 represents the milder end of the POMT2-related disease spectrum, with the m
How is POMT2-related limb-girdle muscular dystrophy R14 inherited?
POMT2-related limb-girdle muscular dystrophy R14 follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
Which specialists treat POMT2-related limb-girdle muscular dystrophy R14?
2 specialists and care centers treating POMT2-related limb-girdle muscular dystrophy R14 are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.